Plus   Neg

Sage Therapeutics (SAGE) Has Dropped To A 3-Month Low After Study Failed

Sage Therapeutics (SAGE) announced Tuesday morning that its Phase 3 trial of brexanolone in the treatment super-refractory status epilepticus failed to meet the primary endpoint.

Sage Therapeutics has gapped open sharply lower this morning and is now down 17.70 at $70.82 on above average volume. The stock has fallen to a 3-month low.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT